Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Continues to progress Phase 1b randomized, double-blind, placebo-controlled trial of ALRN-6924 in patients with p53-mutated non-small cell lung cancer (NSCLC) undergoing chemotherapy Updated planned NSCLC study data readouts include interim results in 2Q22; topline full results in 4Q22 Reported preliminary data on ALRN-6924’s p21-mediated cell cycle arrest in healthy humans Confirmed biomarker-driven mechanism of actionCharacterized time to onset, magnitude and duration of cell cycle arrest, inf
-- Aileron is currently developing ALRN-6924 as a novel, selective chemoprotective agentfor patients with p53-mutated cancer undergoing chemotherapy -- -- Preclinical data demonstrated ALRN-6924’s activation of p21-induced cell cycle arrestin murine bone marrow cells and epithelial mucosa cells in the gastrointestinal (GI) tract -- -- New preclinical findings support further study of ALRN-6924as a potential radioprotective agent -- BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced it will present new preclinical data at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrating a potential secondary application of its novel, selective chemoprotective agent ALRN-6924 to also protect against radiation-ind
Aileron Therapeutics Inc (NASDAQ: ALRN) presented new clinical data at the European Society of Medical Oncology (ESMO21) Virtual Congress 2021 for ALRN-6924, a chemoprotective agent. Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells. The Company presented final results from Phase 1b trial of ALRN-6924 in patients wit
Final results from completed Phase 1b trial in patients with small cell lung cancer (SCLC) receiving second-line topotecan demonstrated ALRN-6924’s ability to reduce neutropenia, thrombocytopenia and anemia caused by chemotherapy, as well as the need for transfusionsPreliminary results from ongoing Phase 1 pharmacology study in healthy volunteers confirmed ALRN-6924’s optimal dose (0.3 mg/kg), its mechanism of action, and demonstrated time to onset, duration and magnitude of its pharmacodynamic
Preliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration and magnitude of pharmacodynamic effectsFinal data from completed Phase 1b study in patients with small cell lung cancer (SCLC) receiving topotecan supporting best-in-class potential of ALRN-6924 BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally trans
BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the upcoming H.C. Wainwright Virtual Global Investment Conference, taking place September 13 – 15, 2021. Dr. Aivado’s presentation will include an update on the company’